The National Cancer Institute is conducting trials of a new test that could determine which cancer patients need to receive chemotherapy and which patients may be able to skip the often-harsh treatment. The Oncotype DX test is intended to evaluate the likelihood of relapse in breast cancer patients who have had tumors removed, and researchers want gene tests for colorectal cancer and other malignancies as well.

Full Story:

Related Summaries